Molecular structure of Bucillamine
Bucillamine (CAS 65002-17-7)
See product citations (1)
Alternate Names:
Thiobutarit; Tiobutarit
Application:
Bucillamine is an antirheumatic agent
CAS Number:
65002-17-7
Molecular Weight:
223.31
Molecular Formula:
C7H13NO3S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Bucillamine is used in research focusing on its antioxidative and cytoprotective properties, primarily due to its capability to modulate cellular redox states. This chemical is studied for its role in inducing the synthesis of glutathione, an important antioxidant in cellular defense mechanisms against oxidative stress. Researchers investigate the effects of Bucillamine on various cell types to understand better how it influences cellular resilience in response to environmental stressors. Additionally, Bucillamine′s potential to act as a chelating agent is explored, particularly in contexts where heavy metal detoxification is crucial.
Bucillamine (CAS 65002-17-7) References
- Bucillamine prevents myocardial reperfusion injury. | Horwitz, LD. and Sherman, NA. 2001. J Cardiovasc Pharmacol. 38: 859-67. PMID: 11707689
- Bucillamine induces membranous glomerulonephritis. | Nagahama, K., et al. 2002. Am J Kidney Dis. 39: 706-12. PMID: 11920335
- Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. | Amersi, F., et al. 2002. Proc Natl Acad Sci U S A. 99: 8915-20. PMID: 12084933
- Bucillamine: a potent thiol donor with multiple clinical applications. | Horwitz, LD. 2003. Cardiovasc Drug Rev. 21: 77-90. PMID: 12847560
- Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature. | Isozaki, T., et al. 1992. Clin Investig. 70: 1036-42. PMID: 1472834
- Bucillamine induces glutathione biosynthesis via activation of the transcription factor Nrf2. | Wielandt, AM., et al. 2006. Biochem Pharmacol. 72: 455-62. PMID: 16806086
- Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases. | Nakagomi, D., et al. 2013. Rheumatol Int. 33: 793-7. PMID: 22090009
- Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes. | Kim, SJ., et al. 2015. Exp Mol Med. 47: e142. PMID: 25697147
- Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis: case report and literature review. | Manabe, S., et al. 2015. Case Rep Nephrol Dial. 5: 30-8. PMID: 25849672
- Bucillamine-induced yellow nail syndrome. | Tanizaki, R., et al. 2017. J Gen Fam Med. 18: 479-480. PMID: 29264101
- Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling. | Nishiya, N., et al. 2019. Pharmaceuticals (Basel). 12: PMID: 31703435
- Bucillamine Inhibits UVB-Induced MAPK Activation and Apoptosis in Human HaCaT Keratinocytes and SKH-1 Hairless Mouse Skin. | Anwar, A., et al. 2020. Photochem Photobiol. 96: 870-876. PMID: 32077107
Inhibitor of:
OPN1MW, and TXNL6.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bucillamine, 10 mg | sc-391874A | 10 mg | $133.00 | |||
Bucillamine, 100 mg | sc-391874 | 100 mg | $337.00 |